HFRS

AIM Vaccine Announces Proposed Listing on the Main Board of SEHK

Retrieved on: 
Friday, September 23, 2022
Global, Safety, IPV, Efficiency, CIC, National Medical Products Administration, RNA transfection, HFRS, HAV, Goldman Sachs, Industry, China International Capital Corporation, Stock exchange, Clinical trial, Mumps, Technology, CDC, Meningococcal disease, Vaccine, US, HPV, Research, International, SEHK, COVID-19, Food, Company, Rabies, NDA, Omicron, Science, Exploration, NMPA, Globe, COVID-19 vaccine, AIM, Culture, L.L.C, National, CTA, Honesty, HBV, CMOS, Public health, Coronavirus, Record, Marketing, GMP, Motherboard, Health, The Group, Program, 2000 Simpsonwood CDC conference, Infection, Pharmaceutical industry, Property management, PRC, Group, Limited

According to CIC, AIM Vaccine is the only China-based vaccine player that has all five proven human vaccine platform technologies worldwide, namely bacterial vaccine technologies, viral vaccine technologies, genetically engineered vaccine technologies, combination vaccine technologies and mRNA vaccine technologies, with at least one approved product or one vaccine candidate at CTA or clinical stages under each platform.

Key Points: 
  • According to CIC, AIM Vaccine is the only China-based vaccine player that has all five proven human vaccine platform technologies worldwide, namely bacterial vaccine technologies, viral vaccine technologies, genetically engineered vaccine technologies, combination vaccine technologies and mRNA vaccine technologies, with at least one approved product or one vaccine candidate at CTA or clinical stages under each platform.
  • AIM Vaccine currently commercializes eight vaccine products against six disease areas, of which the HBV vaccines and human rabies vaccine are its market-leading key commercialized vaccine products.
  • AIM Vaccine acquired Rong'an Bio, AIM Honesty, AIM Kanghuai and AIM Weixin between 2015 and 2017, together with their vaccine products against human rabies, HBV, HAV, mumps and HFRS.
  • AIM Vaccine has leading scientists joining or collaborating with AIM Vaccine to support the Group's vaccine development and manufacturing.

DGAP-News: Atriva receives FDA Orphan Drug Designation for Zapnometinib to treat Hantavirus Infections

Retrieved on: 
Monday, January 10, 2022
Safety, CDC, Viral hemorrhagic fever, RSV, RNP, Risk, Macrophage inflammatory protein, Severe acute respiratory syndrome coronavirus 2, Viral load, Death, Orthohantavirus, CSO, Patient, Orthornavirae, ODD, Chemokine, Gene expression, Category, Orphan drug, Hantavirus pulmonary syndrome, RNA, III, Food, Patent, ECDC, Therapy, Degenerative disease, Cell, Company, Cytoplasm, Cytokine, Human, Vaccine, CEO, COVID-19, FDA, Disease, Gesellschaft mit beschränkter Haftung, Orphan, Fatality, Hantavirus hemorrhagic fever with renal syndrome, HPS, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, MEK, Pharmaceutical industry, HFRS, zapnometinib's mode of action with dual effect, Atriva Therapeutics GmbH, ZAPNOMETINIB'S MODE OF ACTION WITH DUAL EFFECT, ATRIVA THERAPEUTICS GMBH

"Antiviral efficacy of zapnometinib against hantavirus has been previously proven in vitro in an academic collaboration.

Key Points: 
  • "Antiviral efficacy of zapnometinib against hantavirus has been previously proven in vitro in an academic collaboration.
  • Dr. Rainer Lichtenberger, CEO of Atriva Therapeutics, commented: "The Orphan Drug Designation we received for our lead drug candidate zapnometinib is an important milestone towards addressing the urgent needs of patients infected with hantavirus.
  • [1]
    The FDA may grant Orphan Drug Designation (ODD) to support the development and evaluation of new treatments for rare diseases.
  • [11]
    The Atriva lead product zapnometinib (ATR-002) is developed specifically to treat diseases such as influenza and COVID-19, caused by RNA viruses.